1. Introduction
===============

Androgen insensitivity syndrome (AIS) is a rare X-linked recessive androgen receptor (AR) disorder in an individual with 46,XY karyotype. According to the degree of androgen insensitivity, AIS could be classified as complete, partial, or mild AIS. Complete AIS (CAIS) is characterized by complete resistance to the actions of androgens and presented as female appearance and normal breast development, absence of uterus and ovaries, bilateral undescended testis, and elevated testosterone levels. Many studies proved that AR signaling was associated with glucose homeostasis and lipid metabolism.^\[[@R1]--[@R3]\]^ Our case provides the association between CAIS and metabolic disorder, which may contribute to the understanding of the role of AR in metabolic regulation.

2. Case report
==============

A 22-year-old female patient was admitted to our center for the evaluation of high blood sugar in December 14, 2016. She was diagnosed as diabetes by routine examination last year. The fasting glucose at that time was 7.0 mmol/L. However, the patient did not pay any attention to the disease and did not take any oral hypoglycemic agent. One month ago, the patient presented with polyuria, polydipsia, and lost 10 kg of her body weight. Her casual plasma glucose was 20 mmol/L and ketone bodies were negative. The patient was raised as a girl at birth. At 2 years of age, testicles were found in the groin in the course of herniotomy, and then she underwent gonadectomy. The patient has primary amenorrhea and poor secondary sex characteristics after puberty. No further evaluation was conducted for her. The patient was adopted by her foster parents, whereas the information about her blood parents is not available. On physical examination, she had normal blood pressure and her height was 178 cm, weight 85 kg, body mass index 26.8 kg/m^2^, waist circumference 100 cm, and hip circumference 92 cm. The patient presented with infantile female genitalia, absence of breast development, and blind end of the vagina. The study was approved by the ethics committee of Shanghai Tenth People\'s Hospital and the patient has provided informed consent for publication of the case.

Results of the biochemical analysis are listed in Table [1](#T1){ref-type="table"}. The patient exhibited severe dysfunction in lipid profiles: high levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-c), and lower levels of high-density lipoprotein cholesterol (HDL-c). The oral glucose tolerance test showed that peak insulin and c-peptide were 39.63 mmol/L and 4.48 ng/mL, respectively, at 60 minutes. Glycosylated hemoglobin (HbA1c) was 12.8%. Islet cell autoantibodies (ICAs), insulin autoantibody (IAA), and glutamic acid decarboxylase antibody (GADA) were all negative. Serum concentrations of luteinizing hormone (32.5 mU/mL) and follicle-stimulating hormone (43.8 mU/mL) were significantly higher than normal range, whereas estradiol (30.57 pmol/L), testosterone (0.70 nmol/mL), and anti-Müllerian hormone (0.01 ng/mL) were lower than normal range. The laboratory data presented normal basal levels of thyroid hormones, sensitive thyroid stimulating hormone, prolactin, adrenocorticotropic hormone (ACTH), and cortisol (Table [1](#T1){ref-type="table"}). The karyotype is 46,XY. The magnetic resonance imaging of pituitary and the computed tomography of adrenal were normal. Pelvic ultrasonography could not find her ovary and uterus. Mutation c.2751C \> G (p.917F \> L) in exon 8 of *AR* gene was identified in the patient.
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Laboratory findings on admission.
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3. Discussion
=============

Both epidemiological studies and experiment have demonstrated that AR signaling plays a role in glucose homeostasis and lipid metabolism.^\[[@R1]--[@R3]\]^ It was reported that male AR knockout mice showed a risk factor for the development of obesity and metabolic abnormalities.^\[[@R4]\]^ In addition, androgen deficiency in men was associated with increased body fat and impaired insulin sensitivity.^\[[@R4]\]^ Recently, some disorders of sex development are reported to be associated with increased risks of diabetes and metabolic syndrome as well.^\[[@R5]--[@R7]\]^ But there were few data on the components of metabolic syndrome in young women with CAIS.

The diagnosis of CAIS in this patient was established by infantile female genitalia, blind end of the vagina, absence of ovary and uterus, history of gonadectomy, 46,XY karyotype, and detected a mutation in *AR* gene. The mutation c.2751C \> G (p.917F \> L) detected in this patient has been described in an Austrian patient with CAIS.^\[[@R8]\]^ It should be noticed that early gonadectomy could explain the absence of breast development and low levels of testosterone in our patient.

The patient had never received hormone replacement during puberty and post-puberty. At the age of 21 years, she was diagnosed as diabetes. Her diabetes was characterized by no ketoacidosis and negative antibodies for IAA, ICA, and GADA. Her blood glucose levels gradually decreased after a daily dose of insulin of 0.8 U/kg, suggesting an insulin resistance. Considering the patient had central obesity, diabetes, and lower levels of HDL-c, the patient can also be diagnosed with metabolic syndrome according to 2005 International Diabetes Federation Criteria. Those information support the type of diabetes in the patient, which might be type 2 diabetes.

Our data are in agreement with the previous study, which claimed that in women with CAIS, disruption of AR signaling may increase body fat and lead to abnormal values of cholesterol (total and LDL-c) and HOMA-IR.^\[[@R9]\]^ The underlying mechanism might be explained by reduced PI3K activity and *PPARα* gene in the skeletal muscle and the liver, and increased expression of genes that stimulate hepatic glucose production, late adipocyte differentiation, and lipid accumulation.^\[[@R3],[@R4]\]^ Moreover, AR also plays significant roles in central nervous system, which was not only related to various masculine behaviors but also associated the role of neuronal AR in metabolic regulation.^\[[@R3]\]^

For therapy, the patient was treated by insulin, metformin, and statins. Besides the treatment for diabetes and metabolic disorder, estrogen replacement is also required for the patient, which can help in development of secondary sexual characteristics, maintain metabolic health, and promote general wellbeing. After 6 months follow-up, the patient had a good control of blood sugar and lipid profiles. However, the breast development and body weight change were not obvious. Further follow-up should be conducted in the patient.

4. Conclusion
=============

We reported a case of CAIS with diabetes mellitus and metabolic syndrome, which would imply that to recognize special type diabetes among the young-onset diabetic patients is extremely important. Moreover, this case will provide further evidence of a link between impaired AR signaling and metabolic regulation.
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